19. Salvatory R., Gordon M.B., Woodmansee W.W., Ioachimescu A.G., Carver D.W., Mirakhur B. A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary. 2017; 20 (6): 605–18. DOI: https://doi.org/10.1007/s11102-017-0821-y
20. Ezzat S., Caspar-Bell G.M., Chik C.L., et al. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract. 2019; 25 (4): 379–93. DOI: https://doi.org/10.4158/EP-2018-0500
21. Puig-Domingo M., Bernabeu I., Pico A., et al. Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne). 2021; 12: 648411. DOI: https://doi.org/10.3389/fendo.2021.648411
22. Bollerslev J., Heck A., Olarescu N.C. Management of endocrine disease: individualised management of acromegaly. Eur J Endocrinol 2019; 181 (2): 57–71. DOI: https://doi.org/10.1530/EJE-19-0124
23. Fleseriu M., Fuhrer-Sakel D., van der Lely A.J., et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021; 185 (4): 525–38. DOI: https://doi.org/10.1530/EJE-21-0239
24. Nakano-Tateno T., Lau R.J., Wang J., et al. Multimodal non-surgical treatments of aggressive pituitary tumors. Front Endocrinol (Lausanne). 2021; 12: 624686. DOI: https://doi.org/10.3389/fendo.2021.624686
25. Liu W., Xie L., He M., et al. Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues. Int J Endocrinol. 2017; 2017: 9606985. DOI: https://doi.org/10.1155/2017/9606985
26. Melmed S., et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14 (9): 552–61. DOI: https://doi.org/10.1038/s41574-018-0058-5
27. Fleseriu M., Biller B.M.K., Freda P.U., Gadelha M.R., Giustina A., Katznelson L., et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021; 24 (1): 1–13. DOI: https://doi.org/10.1007/s11102-020-01091-7
28. Zarool-Hassan R., et al. Symptoms and signs of acromegaly: an ongoing need to raise awareness among healthcare practitioners. J Prim Health Care. 2016; 8 (2): 157–63. DOI: https://doi.org/10.1071/HC15033
29. Esposito D., Ragnarsson O., Johannsson G., Olsson D.S. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020; 182 (6): 523–31. DOI: https://doi.org/10.1530/EJE-20-0019
30. Antsiferov M.B., Alekseeva T.M., Pronin E.V., Pronin V.S. Predictors of the clinical course and effectiveness of treatment of acromegaly (based on the materials of the Moscow Register). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training] 2020; 9 (3): 26–38. (in Russian)
31. Belaya Zh.E., Golounina O.O., Rozhinskaya L. Ya., Mel’nichenko G.A., et al. Epidemiology. clinical manifestations and effectiveness of various methods of treatment of acromegaly according to the unified Russian register of tumors of the hypothalamic-pituitary system. Problemy endokrinologii [Problems of Endocrinology]. 2020; 66 (1): 93–103. (in Russian)
32. Mete O., Cintosun A., Pressman I., Asa S.L. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol. 2018; 31: 900–9. DOI: https://doi.org/10.1038/s41379-018-0016-8
33. Miermeister C.P., Petersenn S., Buchfelder M., et al. Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun. 2015; 3: 50. DOI: https://doi.org/10.1186/s40478-015-0229-8
34. Espinosa De Los Monteros A.L., Sosa-Eroza E., Gonzalez B., Mendoza V., Mercado M. Prevalence, clinical and biochemical spectrum, and treatment outcome of acromegaly with normal basal GH at diagnosis. J Clin Endocrinol Metab. 2018; 103: 3919–24. DOI: https://doi.org/10.1210/jc.2018-01113
35. Butz L.B., Sullivan S.E., Chandler W.F., Barkan A.L. «Micromegaly»: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary. 2016; 19: 547–51. DOI: https://doi.org/10.1007/s11102-016-0735-0
36. Potorac I., Beckers A., Bonneville J.F. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. Pituitary. 2017; 20 (1): 116–20. DOI: https://doi.org/10.1007/s11102-017-0788-8
37. Kocak B., Durmaz E.S., Kadioglu P., et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019; 29: 2731–9. DOI: https://doi.org/10.1007/s00330-018-5876-2
38. Sarkar S., Chacko A.G. Surgery for acromegaly. Neurol India. 2020; 68 (suppl S 1): 44–51. DOI: https://doi.org/10.4103/0028-3886.287664
39. Kalinin P.L., Kadashev B.A., Fomichev D.V., Kutin M.A., Astaf’eva L.I., Sharipov O.I., et al. Surgical treatment of pituitary adenomas. Voprosy neyrokhirurgii imeni N.N. Burdenko [Problems of Neurosurgery named after N.N. Burdenko]. 2017; 81 (1): 95–107. (in Russian)
40. Raverot G., Burman P., McCormack A., et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018; 178 (1): G1–24. DOI: https://doi.org/10.1530/EJE-17-0796
41. Park S.H., Ku C.R., Moon J.H., Kim E.H., et al. Age- and sex-specific differences as predictors of surgical remission among patients with acromegaly. J Clin Endocrinol Metab. 2018; 103 (3): 909–16. DOI: https://doi.org/10.1210/jc.2017-01844
42. Ioachimescu A.G., Handa T., Goswami N., Pappy A.L. Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients. Endocrine. 2020; 67 (2): 423–32. DOI: https://doi.org/10.1007/s12020-019-02123-4
43. Shaftel K.A, Cole T.S., Little A.S. National trends in hospital readmission following transsphenoidal surgery for pituitary lesions. Pituitary. 2020; 23 (2): 79–91. DOI: https://doi.org/10.1007/s11102-019-01007-0
44. Colao A., Auriemma R.S., Lombardi G., Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011; 32: 247–71. DOI: https://doi.org/10.1210/er.2010-0002
45. Kasuki L, Wildemberg L.E., Gadelha M. Management of endocrine disease: personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018; 178 (3): R 89–100. DOI: https://doi.org/10.1530/EJE-17-1006
46. Asa S.L., Kucharczyk W., Ezzat S. Pituitary acromegaly: not one disease. Endocr Relat Cancer. 2017; 24 (3): C 1–4. DOI: https://doi.org/10.1530/ERC-16-0496
47. Antsiferov M.B., Alekseeva T.M., Pronin E.V., Pronin V.S. Rational pharmacotherapy of acromegaly (focus on adherence to treatment). Farmateka [Pharmateca]. 2021; (4): 24–33. (in Russian)
48. Gadelha M.R., Bronstein M.D., Brue T., et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2: 875–84. DOI: https://doi.org/10.1016/S2213-8587(14)70169-X
49. Ku C.R., Melnikov V., Zhang Z., Lee E.J. Precision therapy in acromegaly caused by pituitary tumors: how close is it to reality? Endocrinol Metab (Seul). 2020; 35 (2): 206–16. DOI: https://doi.org/10.3803/EnM.2020.35.2.206
50. Puig-Domingo M., Marazuela M. Precision medicine in the treatment of acromegaly. Minerva Endocrinol. 2019; 44 (2): 169–75. DOI: https://doi.org/10.23736/S0391-1977.18.02937-1
51. Wildemberg L.E., da Silva Camacho A.H., Miranda R.L., et al. Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands. J Clin Endocrinol Metab. 2021; 106 (7): 2047–56. DOI: https://doi.org/10.1210/clinem/dgab125
52. Nista F., Corica G., Castelletti L., et al. Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective. Front Endocrinol (Lausanne). 2021; 12: 677919. DOI: https://doi.org/10.3389/fendo.2021.677919
53. Lim D.S.T., Freseriu M. Personalized medical treatment of patients with acromegaly: a review. Endocr Pract. 2022; 28 (3): 321–32. DOI: https://doi.org/10.1016/j.eprac.2021.12.017
54. Raverot G., Dantony E., Beauvy J., et al. Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab. 2017; 102: 3368–74. DOI: https://doi.org/10.1210/jc.2017-00773
55. Delemer B., Chanson P., Foubert L., et al. Patients lost to follow-up in acromegaly: results of the ACROSPECT study. Eur J Endocrinol. 2014; 170 (5): 791–7. DOI: https://doi.org/10.1530/EJE-13-0924